CDKN2A anticorps (AA 39-65)

N° du produit ABIN3030639

Détail du produit anti-CDKN2A anticorps

Antigène: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Épitope: AA 39-65

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CDKN2A est non-conjugé

Application: Western Blotting (WB), ELISA

Purification: Antigen affinity purified

Immunogène: A portion of amino acids 39-65 from the mouse protein was used as the immunogen for this Cdkn2a antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the Cdkn2a antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the Cdkn2a antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur CDKN2A

Antigène: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Autre désignation: Cdkn2a (CDKN2A Produits)

Synonymes: anticorps Arf, anticorps p16, anticorps MTS1, anticorps INK4A, anticorps p19ARF, anticorps p16Cdkn2a, anticorps ARF, anticorps CDK4I, anticorps CDKN2, anticorps CMM2, anticorps INK4, anticorps MLM, anticorps MTS-1, anticorps P14, anticorps P14ARF, anticorps P16, anticorps P16-INK4A, anticorps P16INK4, anticorps P16INK4A, anticorps P19, anticorps P19ARF, anticorps TP16, anticorps ARF-INK4a, anticorps INK4a-ARF, anticorps Ink4a/Arf, anticorps Pctr1, anticorps p16(INK4a), anticorps p16INK4a, anticorps p19, anticorps cyclin-dependent kinase inhibitor 2A, anticorps cyclin dependent kinase inhibitor 2A, anticorps Cdkn2a, anticorps LOC100731972, anticorps LOC100340625, anticorps CDKN2A

Sujet: Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.

UniProt: Q64364

Pathways: Mitotic G1-G1/S Phases, Stem Cell Maintenance, Positive Regulation of Endopeptidase Activity, Autophagy, Positive Regulation of Response to DNA Damage Stimulus